

(1) Publication number: 0 579 496 A1

## (12)

## **EUROPEAN PATENT APPLICATION**

(21) Application number: 93305557.6

(22) Date of filing: 15.07.93

(51) Int. CI.5: C07D 401/04, C07D 401/06, C07D 405/04, C07D 409/04, C07D 413/14, C07D 401/14, C07D 409/14, A61K 31/505

30 Priority: 15.07.92 US 913473 14.06.93 US 76431

(43) Date of publication of application: 19.01.94 Bulletin 94/03

(84) Designated Contracting States: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

(71) Applicant: ONO PHARMACEUTICAL CO., LTD. 1-5, Doshomachi 2-chome Chuo-ku Osaka 541 (JP)

(72) Inventor: Lee, Sung Jai 106 Church Street Clarks Summit, PA 18411 (US) inventor: Konishi, Yoshitaka, c/o Minase Res. Institute Ono Pharm. Co Ltd, 1-1 Sakurai 3-chome Shimamoto-cho, Mishima-gun, Osaka 618 (JP) Inventor: Macina, Orest Taras 409 Applewood Acres Clarks Summit, PA 18411 (US)

inventor: Kondo, Kigen, c/o Minase Res. Ono Pharm. Co. Ltd, 1-1 Sakurai 3-chome

Shimamoto-cho, Mishima-gun, Osaka 618 (JP) Inventor: Yu, Dingwei Tim 210 Frost Hollow Road Easton, Pa 18042 (US)

74) Representative: Bentham, Stephen J.A. Kemp & Co. 14 South Square Gray's Inn London, WC1R 5LX (GB)

(1)

(54) 4-Aminoquinazoline derivatives, and their use as medicine.

The compounds of the formula:

$$(R^4)_n$$
 $N$ 
 $Z$ 
 $CyB$ 
 $(R^3)_m$ 

wherein R1 is H or alkyl;

Y is bond or alkylene;

A is

(i) -CyA-(R<sup>2</sup>)I, (ii) -O-R<sup>0</sup> or -S(O)p-R<sup>0</sup> or

(iii) -NR16R17;

CyA is

(1) 3-7 membered monocyclic carbocyclic ring,

(2) 4-7 membered monocyclic hetero ring containing as hetero atoms, one N atom, one N and one O atoms, two N and one O atoms, or one N and two O atoms,

(3) 4-7 membered monocyclic hetero ring containing as hetero atoms, 1 or 2 O or S atoms;  $R^2$  is (1) H, (2) alkyl, (3) alkoxy, (4) -COOR<sup>5</sup>, in which  $R^5$  is H or alkyl, (5) -NR<sup>6</sup>R<sup>7</sup>, (6) -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, (7) halogen, (8) CF<sub>3</sub>, (9) NO<sub>2</sub> or (10) CF<sub>3</sub>O;

Z is bond, methylene, ethylene, vinylene or ethynylene;

R3 is H, alkyl, alkoxy, halogen or CF3;

and acid addition salts thereof, salts thereof, and hydrates thereof; have inhibitory effect on cGMP-PDE, or additionally on TXA2 synthetase.